- Home
- XMTR vs EWTX Comparison
XMTR vs EWTX Comparison
Compare XMTR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XMTR
- EWTX
- Stock Information
- Founded
- XMTR 2013
- EWTX 2017
- Country
- XMTR United States
- EWTX United States
- Employees
- XMTR N/A
- EWTX N/A
- Industry
- XMTR Industrial Machinery/Components
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- XMTR Technology
- EWTX Health Care
- Exchange
- XMTR Nasdaq
- EWTX Nasdaq
- Market Cap
- XMTR 1.6B
- EWTX 1.5B
- IPO Year
- XMTR 2021
- EWTX 2021
- Fundamental
- Price
- XMTR $32.62
- EWTX $14.12
- Analyst Decision
- XMTR Buy
- EWTX Buy
- Analyst Count
- XMTR 11
- EWTX 9
- Target Price
- XMTR $34.82
- EWTX $39.89
- AVG Volume (30 Days)
- XMTR 605.9K
- EWTX 608.9K
- Earning Date
- XMTR 08-07-2025
- EWTX 08-07-2025
- Dividend Yield
- XMTR N/A
- EWTX N/A
- EPS Growth
- XMTR N/A
- EWTX N/A
- EPS
- XMTR N/A
- EWTX N/A
- Revenue
- XMTR $573,810,000.00
- EWTX N/A
- Revenue This Year
- XMTR $21.52
- EWTX N/A
- Revenue Next Year
- XMTR $17.20
- EWTX N/A
- P/E Ratio
- XMTR N/A
- EWTX N/A
- Revenue Growth
- XMTR 19.35
- EWTX N/A
- 52 Week Low
- XMTR $11.33
- EWTX $10.60
- 52 Week High
- XMTR $45.33
- EWTX $38.12
- Technical
- Relative Strength Index (RSI)
- XMTR 46.64
- EWTX 52.19
- Support Level
- XMTR $31.62
- EWTX $13.34
- Resistance Level
- XMTR $36.08
- EWTX $14.66
- Average True Range (ATR)
- XMTR 1.72
- EWTX 0.59
- MACD
- XMTR -0.37
- EWTX 0.15
- Stochastic Oscillator
- XMTR 22.18
- EWTX 72.86
About XMTR Xometry Inc.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.